Displaying drugs 7326 - 7350 of 8028 in total
VCA-894A
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
Matched Description: … VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of …
Nitroxoline
Nitroxoline is a urinary antibacterial agent active against susceptible gram-positive and gram-negative organisms commonly found in urinary tract infections. It is a hydroxyquinoline derivative unrelated to other classes of drugs. Nitroxoline is active against bacterial gyrases.
Experimental
Matched Description: … It is a hydroxyquinoline derivative unrelated to other classes of drugs. …
Daledalin
Daledin (UK-3557-15) is a selective norepinephrine reuptake inhibitor. It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties. It was in trials for depression in the 1970s but never marketed.
Experimental
Matched Description: … It has no effects on the reuptake of serotonin or dopamine, and no antihistamine or anticholinergic properties …
Magnesium aspartate
Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement. It displays high oral bioavailability and water solubiltiy compared to other magnesium salts such as magnesium citrate, magnesium carbonate and magnesium oxide.
Experimental
Matched Description: … Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement …
Talacotuzumab
Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123. It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission).
Investigational
Matched Description: … It is under investigation in clinical trial NCT01632852 (A Study of CSL362 in Patients With CD123+ Acute …
Sovleplenib
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting spleen tyrosine kinase (Syk). It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly Patients With Acute Myeloid Leukemia).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03483948 (Phase I Study of Hmpl-523+azacitidine in Elderly …
SRP-9005
SRP-9005 is a rAAVrh74 vector containing a codon-optimized human SGCG transgene. Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of Limb-girdle muscular dystrophy (LGMD) type 2C/R5.
Investigational
Matched Description: … Developed by the Kurt+Peter Foundation and Sarepta Therapeutics, it is being investigated for the treatment of …
Cyanamide
A cyanide compound which has been used as a fertilizer, defoliant and in many manufacturing processes. It often occurs as the calcium salt, sometimes also referred to as cyanamide. The citrated calcium salt is used in the treatment of alcoholism. [PubChem]
Experimental
Matched Description: … The citrated calcium salt is used in the treatment of alcoholism. [PubChem] …
D-Asparagine
A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain tissue. It is biosynthesized from ASPARTIC ACID and AMMONIA by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)
Experimental
Matched Description: … A non-essential amino acid that is involved in the metabolic control of cell functions in nerve and brain …
LY2275796
LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.
Investigational
Matched Description: … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of …
ATG-Fresenius S
ATG-Fresenius S is a concentrated anti-human T-lymphocyte immunoglobulin preparation derived from rabbits after immunization with a T-lympoblast cell line. ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following organ transplantation.
Investigational
Matched Description: … ATG-Fresenius S is an immunosuppressive product for the prevention and treatment of acute rejection following …
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide
(Z)-2-[2-(4-methylpiperazin-1-yl)benzyl]diazenecarbothioamide is a solid. This compound belongs to the phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group. This drug targets the protein S100B.
Experimental
Matched Description: … These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a …
Methylmethionine chloride
Methylmethionine chloride may be useful in helping the healing of gastric ulcers. In Japan, it is used as an over the counter product for gastrointestinal health support. It is also called "Vitamin U", but it is not a true vitamin.
Experimental
Matched Description: … Methylmethionine chloride may be useful in helping the healing of gastric ulcers. …
SR-9009
SR-9009 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of …
SR-9011
SR-9011 is a REV-ERB agonist. SR-9011 has been demonstrated that it is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of normal cells or tissues .
Experimental
Matched Description: … and oncogene-induced senescent cells, including melanocytic naevi, and has no effect on the viability of …
Uprifosbuvir
Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir (MK-5172) and Uprifosbuvir (MK-3682) With Elbasvir (MK-8742) or Ruzasvir (MK-8408) for Chronic Hepatitis C Genotype (GT)1 and GT2 Infection (MK-3682-011)).
Investigational
Matched Description: … Uprifosbuvir is under investigation in clinical trial NCT02332707 (Efficacy and Safety of Grazoprevir …
Inavolisib
Inavolisib (GDC-0077) is under investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of GDC-0077 Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer).
Investigational
Matched Description: … investigation in clinical trial NCT03006172 (To Evaluate the Safety, Tolerability, and Pharmacokinetics of …
Cinaciguat
Cinaciguat is under investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of Lower Doses Cinaciguat (25 ΜG/h, 10 ΜG/h) Given Intravenously to Patients With Acute Decompensated Chronic Congestive Heart Failure (ADHF)).
Investigational
Matched Description: … investigation in clinical trial NCT01067859 (A Phase Iib Study to Investigate the Efficacy and Tolerability of …
FF-10501-01
FF-10501-01 is a novel, selective inosine monophosphate dehydrogenase (IMPDH) inhibitor with anticancer activity. FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome).
Investigational
Matched Description: … [A257306] FF-10501-01 is under investigation in clinical trial NCT03486353 (A Study of FF-10501-01 in …
SS1(dsFv)-PE38
SS1(dsFv)-PE38 is a recombinant anti-mesothelin immunotoxin. SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-small Cell Lung Adenocarcinoma).
Investigational
Matched Description: … SS1(dsFv)-PE38 is under investigation in clinical trial NCT01051934 (A Phase I Trial of SS1 (Dsfv) PE38 …
Droloxifene
Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM). Droloxifene also exhibits more rapid pharmacokinetics, reaching peak concentrations and being eliminated much more rapidly than tamoxifen. Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell...
Investigational
Matched Description: … Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor ... affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of ... Droloxifene may also be a potentially useful agent for the treatment of postmenopausal osteoporosis because …
CYT006-AngQb
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Allogeneic Cardiosphere-Derived Cells
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
Displaying drugs 7326 - 7350 of 8028 in total